Abstract:Abstract Background In spite of the significant escalation in the depth of our conception and regulation of breast cancer over the past decades, the malady is still a serious community health challenge globally and poses a substantial tasks. Selective estrogen modulators (SERMs) such as Tamoxifen are approved for the therapy of this illness but developed drug resistance and unwanted side effects such as endometrial cancer caused by the long-term Tamoxifen chemotherapy limit their therapeutic applicability. Hence, developing new ER + drugs with better therapeutic effect is strongly needed. In an attempt to overcome this challenge, this research is aimed at designing novel chromen-2-one analogues with better inhibition capacity against MCF-7 breast cancer cell line via structural modification of the reference compound and predict their activities using a developed QSAR model. Results Four models were developed, and the first was selected for the design as it has the highest statistical parameters such as: coefficient of determination ( R 2 = 0.950), cross-validation coefficient ( Q cv 2 = 0.912), adjusted R 2 ( R adj 2 = 0.935), and external validation R 2 ( R pred 2 = 0.7485). Twelve (12) new novel chromen-2-one analogs were designed through structural modification of the reference compound. Their activities was predicted using the selected model, and their pIC 50 was found to be better than that of the reference compound and standard drug (Tamoxifen) used in the research. Results of pharmacokinetic study of the designed compounds revealed that they possess drug-likeness properties as none of them violated the Lipinski’s rule of five while ADMET studies confirmed designed compounds 6, 8, 11 and 12 as orally safe and non-toxic. Furthermore, molecular docking analysis was performed between these orally safe designed compounds and the active site of the ER + receptor and the result showed that they have higher binding affinities than the reference compound and the standard drug used for this research. Conclusion Hence, designed compounds 6, 8, 11 and 12 can be used as novel ER + breast cancer drug candidates after performing in vivo and in vitro studies.

Design, Synthesis and Antibreast Cancer Mcf-7 Cells Biological Evaluation of Heterocyclic Analogs of Resveratrol

Design, Synthesis and Biological Evaluation of a Series of New Resveratrol Analogues As Potential Anti-Cancer Agents

Synthesis and Estrogen-Like Activity of Resveratrol Analogues

Synthesis and Biological Evaluation of Resveratrol–coumarin Hybrid Compounds As Potential Antitumor Agents

Design, Synthesis and Biological Evaluation of Novel Indone Derivatives As Selective ERβ Modulators

Design, Synthesis, Molecular Modeling, and Biological Evaluation of Pyrazole-Naphthalene Derivatives As Potential Anticancer Agents on MCF-7 Breast Cancer Cells by Inhibiting Tubulin Polymerization.

Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer.

Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents.

Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents

Synthesis and Bio-evaluation of 2-Alkyl Substituted Fluorinated Genistein Analogues Against Breast Cancer.

Synthesis and Anti-Proliferation Activity Evaluation on MCF-7 Cells of Stilbenenitrile Sulfonamide Analogues

Design, Synthesis, and Evaluation of Methoxylated Resveratrol Derivatives As Potential Antitumor Agents

Structure-based design, synthesis and biological evaluation of N-substituted 6H-thiochromeno[2,3–c]quinolin-12(12H)-ones as potential breast cancer drugs

3-Acyl-5-hydroxybenzofuran derivatives as potential anti-estrogen breast cancer agents: A combined experimental and theoretical investigation

The Design, Synthesis, and Anti-Tumor Mechanism Study of N-phosphoryl Amino Acid Modified Resveratrol Analogues.

Synthesis and evaluation of novel substituted 5-hydroxycoumarin and pyranocoumarin derivatives exhibiting significant antiproliferative activity against breast cancer cell lines.

Design, synthesis and anticancer activity of novel steroidal derivatives with D‐ring fused or substituted N‐heterocyclic systems

Synthesis, Preliminary Structure-Activity Relationships and Biological Evaluation of Pyridinyl-4,5-2h-isoxazole Derivatives As Potent Antitumor Agents

Computational modeling, ligand-based drug design, drug-likeness and ADMET properties studies of series of chromen-2-ones analogues as anti-cancer agents

Design, Synthesis and Biological Evaluation of Resveratrol-Cinnamoyl Derivates As Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site.

Synthesis and Biological Evaluation of Macamides Derivatives as Potent Inhibitors of Breast Cancer Cell MCF-7